Journal Mobile Options
Table of Contents
Vol. 82, No. 2, 2005
Issue release date: February 2006
Section title: Original Paper
Neuroendocrinology 2005;82:111–120
(DOI:10.1159/000091206)

Differential Protective Properties of Estradiol and Tamoxifen against Methamphetamine-Induced Nigrostriatal Dopaminergic Toxicity in Mice

D’Astous M. · Mickley K.R. · Dluzen D.E. · Di Paolo T.
aMolecular Endocrinology and Oncology Research Center, Laval University Medical Center, CHUL, and Faculty of Pharmacy, Laval University, Quebec City, Canada, and bDepartment of Anatomy, Northeastern Ohio Universities College of Medicine (NEOUCOM), Rootstown, Ohio, USA

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restriction apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 7/7/2005
Accepted: 11/24/2005
Published online: 2/22/2006

Number of Print Pages: 10
Number of Figures: 5
Number of Tables: 0

ISSN: 0028-3835 (Print)
eISSN: 1423-0194 (Online)

For additional information: http://www.karger.com/NEN

Abstract

Mechanisms implicated in protective potential of estrogens are poorly understood. Tamoxifen, a selective estrogen receptor modulator (SERM), presents a neuroprotective effect against methamphetamine (MA)- and methoxy-phenyltetrahydropyridine (MPTP)-induced toxicity when used alone but abolishes estrogen’s positive effects when combined with this hormone. In order to understand tamoxifen’s protective properties, the present study compared it to estradiol on several markers of dopaminergic neurons to achieve a relatively comprehensive comparison between these two agents. Estradiol benzoate (E) or tamoxifen were used at different concentrations (E: 1, 10 or 40 µg; tamoxifen: 12.5, 125 or 500 µg) 24 h prior to a MA injection in ovariectomized CD-1 mice. The effects of the lesion and treatments were studied on striatal dopamine (DA) concentrations, dopamine and monoamine vesicular transporters (DAT and VMAT2), and preproenkephalin (PPE) mRNA levels. Both treatments, at all concentrations, prevented the MA-induced decrease of striatal DA concentrations and VMAT2 binding. Only E was able to prevent loss of DAT binding in the lateral striatum and to attenuate the MA-induced increase in striatal PPE mRNA levels (at 1 or 40 µg). Therefore, in this paradigm, E and tamoxifen differentially modulated MA-induced neuronal damages. While both treatments prevented the DA decrease, E protected more efficiently other dopaminergic parameters suggesting that overall E is more effective than tamoxifen as a neuroprotectant of the nigrostriatal dopaminergic system.


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 7/7/2005
Accepted: 11/24/2005
Published online: 2/22/2006

Number of Print Pages: 10
Number of Figures: 5
Number of Tables: 0

ISSN: 0028-3835 (Print)
eISSN: 1423-0194 (Online)

For additional information: http://www.karger.com/NEN


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Baldereschi M, Di Carlo A, Rocca WA, Vanni P, Maggi S, Perissinotto E, Grigoletto F, Amaducci L, Inzitari D: Parkinson’s disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. Neurology 2000;55:1358–1363.
  2. Wooten GF, Currie LJ, Bovbjerg VE, Lee JK, Patrie J: Are men at greater risk for Parkinson’s disease than women? J Neurol Neurosurg Psychiatry 2004;75:637–639.
  3. Saunders-Pullman R, Gordon-Elliott J, Parides M, Fahn S, Saunders HR, Bressman S: The effect of estrogen replacement on early Parkinson’s disease. Neurology 1999;52:1417–1421.
  4. Currie LJ, Harrison MB, Trugman JM, Bennett JP, Wooten GF: Postmenopausal estrogen use affects risk for Parkinson disease. Arch Neurol 2004;61:886–888.
  5. Dluzen DE: Neuroprotective effects of estrogen upon the nigrostriatal dopaminergic system. J Neurocytol 2000;29:387–399.
  6. Dluzen DE, McDermott JL, Anderson LI: Tamoxifen diminishes methamphetamine-induced striatal dopamine depletion in intact female and male mice. J Neuroendocrinol 2001;13:618–624.
  7. Gao X, Dluzen DE: Tamoxifen abolishes estrogen’s neuroprotective effect upon methamphetamine neurotoxicity of the nigrostriatal dopaminergic system. Neuroscience 2001;103:385–394.
  8. Gajjar TM, Anderson LI, Dluzen DE: Acute effects of estrogen upon methamphetamine induced neurotoxicity of the nigrostriatal dopaminergic system. J Neural Transm 2003;110:1215–1224.
  9. D’Astous M, Gajjar TM, Dluzen DE, Di Paolo T: Dopamine transporter as a marker of neuroprotection in methamphetamine-lesioned mice treated acutely with estradiol. Neuroendocrinology 2004;79:296–304.
  10. Dluzen DE, McDermott JL, Liu B: Estrogen as a neuroprotectant against MPTP-induced neurotoxicity in C57/B1 mice. Neurotoxicol Teratol 1996;18:603–606.
  11. Callier S, Morissette M, Grandbois M, Pelaprat D, Di Paolo T: Neuroprotective properties of 17β-estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice. Synapse 2001;41:131–138.
  12. Gerlach M, Riederer P: Animal models of Parkinson’s disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm 1996;103:987–1041.
  13. Popat RA, Van DenEeden SK, Tanner CM, McGuire V, Bernstein AL, Bloch DA, Leimpeter A, Nelson LM: Effect of reproductive factors and postmenopausal hormone use on the risk of Parkinson disease. Neurology 2005;65:383–390.
  14. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women’s Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321–333.
  15. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, Hendrix SL, Jones BN 3rd, Assaf AR, Jackson RD, Kotchen JM, Wassertheil-Smoller S, Wactawski-Wende J, WHIMS Investigators: Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. The Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA 2003;289:2651–2662.
  16. Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner RL, Manson JE, Gass ML, Stefanick ML, Lane DS, Hays J, Johnson KC, Coker LH, Dailey M, Bowen D, WHIMS Investigators: Effect of estrogen plus progestin on global cognitive function in postmenopausal women. The Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA 2003;289:2663–2672.
  17. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O’Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S, Women’s Health Initiative Steering Committee: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004;291:1701–1712.
  18. Dhandapani KM, Brann DW: Protective effects of estrogen and selective estrogen receptor modulators in the brain. Biol Reprod 2002;67:1379–1385.
  19. Smith CL, O’Malley BW: Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 2004;25:45–71.
  20. Dluzen DE, McDermott JL, Anderson LI: Tamoxifen eliminates estrogen’s neuroprotective effect upon MPTP-induced neurotoxicity of the nigrostriatal dopaminergic system. Neurotoxicol Res 2001;3:291–300.
  21. Obata T, Kubota S: Protective effect of tamoxifen on 1-methyl-4-phenylpyridine-induced hydroxyl radical generation in the rat striatum. Neurosci Lett 2001;308:87–90.
  22. Davidson C, Gow AJ, Lee TH, Ellinwood EH: Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Brain Res Rev 2001;36:1–22.
  23. Jourdain S, Morissette M, Morin N, Di Paolo T: Oestrogens prevent loss of dopamine transporter and vesicular monoamine transporter 2 in substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice. J Neuroendocrinol 2005;17:509–517.
  24. Ekue A, Boulanger JF, Morissette M, Di Paolo T: Lack of effect of testosterone and dihydrotestosterone compared to 17β-oestradiol in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice. J Neuroendocrinol 2002;14:731–736.
  25. Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, Anthony RM, Schmunk GA, Shannak K, Haycock JW, Kish SJ: Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 1996;2:699–703.
  26. Bezard E, Gross CE, Brotchie JM: Presymptomatic compensation in Parkinson’s disease is not dopamine-mediated. Trends Neurosci 2003;26:215–221.
  27. McDermott JL, Anderson LI, Dluzen DE: Tamoxifen treatment of ovariectomized mice alters dopamine release from striatal tissue fragments superfused in vitro. Brain Res 1995;698:248–252.
  28. Kilbourn M, Frey K: Striatal concentrations of vesicular monoamine transporters are identical in MPTP-sensitive (C57BL/6) and -insensitive (CD-1) mouse strains. Eur J Pharmacol 1996;307:227–232.
  29. Franklin K, Paxinos G: The Mouse Brain in Stereotaxic Coordinates. San Diego, Academic Press, 1997.
  30. Scherman D, Raisman R, Ploska A, Agid Y: [3H]dihydrotetrabenazine, a new in vitro monoaminergic probe for human brain. J Neurochem 1988;50:1131–1136.
  31. Morissette M, Di Paolo T: Sex and estrous cycle variations of rat striatal dopamine uptake sites. Neuroendocrinology 1993;58:16–22.
  32. Morissette M, Di Paolo T: Effect of chronic estradiol and progesterone treatments of ovariectomized rats on brain dopamine uptake sites. J Neurochem 1993;60:1876–1883.
  33. Calon F, Birdi S, Rajput AH, Hornykiewicz O, Bedard PJ, Di Paolo T: Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias. J Neuropathol Exp Neurol 2002;61:186–196.
  34. Ricaurte GA, Guillery RW, Seiden LS, Schuster CR, Moore RY: Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain. Brain Res 1982;235:93–103.
  35. Wang JQ, McGinty JF: D1 and D2 receptor regulation of preproenkephalin and preprodynorphin mRNA in rat striatum following acute injection of amphetamine or methamphetamine. Synapse 1996;22:114–122.
  36. Vander Borght T, Kilbourn M, Desmond T, Kuhl D, Frey K: The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur J Pharmacol 1995;294:577–583.
  37. Wilson JM, Kish SJ: The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat. J Neurosci 1996;16:3507–3510.
  38. Weisz A, Rosales R: Identification of an estrogen response element upstream of the human c-fos gene that binds the estrogen receptor and the AP-1 transcription factor. Nucleic Acids Res 1990;18:5097–5106.
  39. Hall JM, McDonnell DP: The estrogen receptor β-isoform of the human estrogen receptor modulates ERα transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 1999;140:5566–5578.
  40. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ, Scanlan TS: Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science 1997;277:1508–1510.
  41. Webb P, Lopez GN, Uht RM, Kushner PJ: Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol Endocrinol 1995;9:443–456.
  42. Kuroki Y, Fukushima K, Kanda Y, Mizuno K, Watanabe Y: Neuroprotection by estrogen via extracellular signal-regulated kinase against quinolinic acid-induced cell death in the rat hippocampus. Eur J Neurosci 2001;13:472–476.
  43. Bi R, Broutman G, Foy MR, Thompson RF, Baudry M: The tyrosine kinase and mitogen-activated protein kinase pathways mediate multiple effects of estrogen in hippocampus. Proc Natl Acad Sci USA 2000;97:3602–3607.
  44. Brunet A, Datta SR, Greenberg ME: Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway. Curr Opin Neurobiol 2001;11:297–305.
  45. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997;91:231–241.
  46. Dubal DB, Shughrue PJ, Wilson ME, Merchenthaler I, Wise PM: Estradiol modulates bcl-2 in cerebral ischemia: a potential role for estrogen receptors. J Neurosci 1999;19:6385–6393.
  47. Cardona-Gomez GP, Mendez P, DonCarlos LL, Azcoitia I, Garcia-Segura LM: Interactions of estrogens and insulin-like growth factor-I in the brain: implications for neuroprotection. Brain Res Brain Res Rev 2001;37:320–334.
  48. Mendez P, Azcoitia I, Garcia-Segura LM: Estrogen receptor α forms estrogen-dependent multimolecular complexes with insulin-like growth factor receptor and phosphatidylinositol 3-kinase in the adult rat brain. Brain Res Mol Brain Res 2003;112:170–176.
  49. Cheng CM, Cohen M, Wang J, Bondy CA: Estrogen augments glucose transporter and IGF-1 expression in primate cerebral cortex. FASEB J 2001;15:907–915.
  50. Manji HK, Bebchuk JM, Moore GJ, Glitz D, Hasanat KA, Chen G: Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: therapeutic implications. J Clin Psychiatry 1999;60(suppl 2): 27–39.

    External Resources

  51. Manji HK, Chen G: PKC, MAP kinases and the bcl-2 family of proteins as long-term targets for mood stabilizers. Mol Psychiatry 2002;7(suppl 1):S46–S56.

    External Resources

  52. Moosmann B, Behl C: The antioxidant neuroprotective effects of estrogens and phenolic compounds are independent from their estrogenic properties. Proc Natl Acad Sci USA 1999;96:8867–8872.